Analysis of the Structural Basis of Specificity of Inhibition of the Abl Kinase by STI571
Open Access
- 1 August 2002
- journal article
- Published by Elsevier BV
- Vol. 277 (35), 32214-32219
- https://doi.org/10.1074/jbc.m111525200
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Roots of Clinical Resistance to STI-571 Cancer TherapyScience, 2001
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaNew England Journal of Medicine, 2001
- Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine KinaseScience, 2000
- Chronic Myelogenous Leukemia: Biology and TherapyAnnals of Internal Medicine, 1999
- Chronic Myeloid LeukemiaNew England Journal of Medicine, 1999
- Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cellsNature Medicine, 1996
- Acute leukaemia in bcr/abl transgenic miceNature, 1990
- Induction of Chronic Myelogenous Leukemia in Mice by the P210
bcr/abl
Gene of the Philadelphia ChromosomeScience, 1990